BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has earned an average recommendation of “Buy” from the ten ratings firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating on the company. The average 1-year price target among brokers that have covered the stock in the last year is $9.00.
A number of analysts have recently weighed in on BCRX shares. Noble Financial reiterated a “buy” rating on shares of BioCryst Pharmaceuticals in a research note on Saturday, May 6th. Zacks Investment Research lowered shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, May 8th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of BioCryst Pharmaceuticals in a research note on Friday, May 19th.
A number of hedge funds have recently added to or reduced their stakes in BCRX. Principal Financial Group Inc. raised its stake in BioCryst Pharmaceuticals by 0.3% in the first quarter. Principal Financial Group Inc. now owns 13,250 shares of the biotechnology company’s stock valued at $111,000 after buying an additional 45 shares in the last quarter. Janney Montgomery Scott LLC raised its stake in BioCryst Pharmaceuticals by 4.7% in the second quarter. Janney Montgomery Scott LLC now owns 33,335 shares of the biotechnology company’s stock valued at $185,000 after buying an additional 1,500 shares in the last quarter. Comerica Bank raised its stake in BioCryst Pharmaceuticals by 18.8% in the fourth quarter. Comerica Bank now owns 16,105 shares of the biotechnology company’s stock valued at $100,000 after buying an additional 2,552 shares in the last quarter. Federated Investors Inc. PA raised its stake in BioCryst Pharmaceuticals by 3.7% in the fourth quarter. Federated Investors Inc. PA now owns 83,835 shares of the biotechnology company’s stock valued at $531,000 after buying an additional 2,983 shares in the last quarter. Finally, American International Group Inc. raised its stake in BioCryst Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 45,230 shares of the biotechnology company’s stock valued at $380,000 after buying an additional 2,989 shares in the last quarter. Institutional investors own 84.57% of the company’s stock.
BioCryst Pharmaceuticals (NASDAQ BCRX) traded up 3.33% during midday trading on Friday, reaching $5.27. 587,268 shares of the company’s stock were exchanged. The stock’s market capitalization is $423.81 million. The stock’s 50-day moving average is $5.63 and its 200-day moving average is $6.38. BioCryst Pharmaceuticals has a 12-month low of $3.56 and a 12-month high of $9.25.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Thursday, May 4th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.01. BioCryst Pharmaceuticals had a negative net margin of 150.24% and a negative return on equity of 323.86%. The business had revenue of $9.40 million for the quarter, compared to analyst estimates of $6.13 million. During the same quarter in the prior year, the business posted ($0.31) EPS. BioCryst Pharmaceuticals’s revenue for the quarter was up 95.8% compared to the same quarter last year. On average, equities analysts forecast that BioCryst Pharmaceuticals will post ($0.73) earnings per share for the current year.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
